Eurofins A.I CyberSecurity Scoring
01/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Eurofins in 2026.
No incidents recorded for Eurofins in 2026.
No incidents recorded for Eurofins in 2026.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Latest updates, reports, and threat intel affecting the global network.
Clinical Diagnostics paid millions in ransom after 485000 patient files were hacked. Nova criminals published only part of 300GB of data.
Personal health data from more than 485000 women has been stolen from a cervical cancer screening programme in the Netherlands.
Hackers steal data from 485000 women at a laboratory that conducts cervical cancer screening. Test results remain reliable.
Eurofins MET Labs is proud to announce the completion of a half-million-dollar expansion of its 10-meter EMC Chamber at their Santa Clara...
Pictured is Dhruv Bisani, Eurofins Cyber Security's (Commissum) Head of Red Team, who writes of red teaming as a defence tactic against...
Eurofins Scientific has agreed to offload its Digital Testing business to Stirling Square Capital Partners in a 220 million deal.
We have advised Eurofins Scientific (EUFI.PA), the global leader in food testing and a global scientific leader in bioanalytical testing,...
Global law firm White & Case LLP has advised investment management firm Barings on a unitranche financing for Stirling Square's acquisition...
Stirling Square Capital Partners announced on Monday that it has reached an agreement with Eurofins Scientific to buy Eurofins Digital Testing for €220 million.
Klever-Go is the Go implementation of the Klever blockchain protocol. Versions from 1.7.14 through 1.7.17 are vulnerable to a remotely triggerable denial of service. Both REST APIs are started with the Gin Engine.Run convenience method, which serves requests through Go's default HTTP server with no ReadHeaderTimeout, ReadTimeout, or MaxHeaderBytes configured. As a result, incoming connections that never complete their request headers are held open indefinitely. When a REST listener is reachable beyond localhost through the documented all-interface bind or a Docker port-publish deployment, a single unauthenticated client can open many slow-header connections and hold them open until server file descriptors are exhausted, preventing the API from accepting new connections. This renders the REST API unavailable to legitimate clients. This issue is fixed in version 1.7.18.
Klever-Go is the Go implementation of the Klever blockchain protocol. In versions 1.7.14 through 1.7.17, the direct-message ingress handler spawns a new goroutine for every incoming direct message before the processor-level antiflood layer makes any admission decision, with no semaphore, throttler, or bound on the number of concurrent in-flight spawns. Because the antiflood check runs inside the spawned goroutine rather than before it, a single connected peer can open a direct-send stream and send a stream of well-formed messages to force unbounded goroutine creation, where each goroutine allocates its own stack and holds a message reference until processing completes, adding scheduler and garbage-collection pressure faster than the runtime can drain it. This lets one peer degrade the node's availability and its ability to process legitimate traffic, resulting in a remotely triggerable denial of service. The issue is fixed in 1.7.18.
Klever-Go is the Go implementation of the Klever blockchain protocol. Versions 1.7.14 through 1.7.17 are vulnerable to a nil-pointer panic triggered by a protobuf Transaction whose embedded RawData sub-message is omitted. This omission causes RawData to decode to nil. Every transaction gossiped on the Klever-Go P2P network is decoded and validated synchronously inside the libp2p pubsub topic-validator callback, where txVersionChecker.CheckTxVersion dereferences tx.RawData.Version with no nil check. Because the libp2p pubsub callback, the underlying go-libp2p-pubsub validation worker, and Klever's own network/p2p layer install no recover(), the panic propagates and crashes the entire node process. The attacker payload is a 3-byte protobuf message; no validator key, stake, funds, or on-chain account is required, and delivery aimed at enough of the BLS validator set can halt block production, resulting in a chain halt. This issue has been fixed in version 1.7.18.
Klever-Go is the Go implementation of the Klever blockchain protocol. In versions prior to 1.7.18, the account-data trie syncers are vulnerable to a resource-exhaustion flaw that leaks bounded throttler slots on error paths. In syncDataTrie() (in both userAccountsSyncer.go and kappAccountsSyncer.go), StartProcessing() reserves a slot from the NumGoRoutinesThrottler, but the corresponding EndProcessing() is only called on the success path and on the duplicate-root early return. As a result, any error from trie.NewTrie(), trie.NewTrieSyncer(), or trieSyncer.StartSyncing() (including the network-dependent timeout path) permanently consumes one slot for the lifetime of the throttler. An attacker who can repeatedly cause trie-node sync failures or timeouts during bootstrap can exhaust the bounded throttler, after which further account-data trie syncs stop making progress and SyncAccounts() returns a timeout. Because epoch bootstrap in syncUserAccountsState() and syncKappAccountsState() aborts on any such error, this causes bootstrap to fail, a core availability issue affecting fresh, restarting, or resyncing nodes and validators. This issue is fixed in version 1.7.18.
Ruby LSP is an implementation of the language server protocol for Ruby. Several workspace-level settings in the Ruby LSP VS Code extension prior to version 0.10.4 could override the path to the Ruby executable, the version manager executables, or the Bundler `Gemfile` used at startup. A malicious repository containing a `.vscode/settings.json` could set these values to attacker-controlled targets. Opening and trusting the repository would then execute code with the privileges of the developer. The Ruby LSP gem and clients of the language server in other editors are not affected. Version 0.10.4 of the Ruby LSP VS Code extension fixes the issue.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.